ACELARATE: A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with gemcitabine in patients with metastatic pancreatic carcinoma.



Palmer, Daniel H ORCID: 0000-0002-7147-5703, Ross, Paul J, Silcocks, Paul, Greenhalf, William ORCID: 0000-0002-1865-3195, Faluyi, Olusola Olusesan, Ma, Yuk Ting, Wadsley, Jonathan, Rawcliffe, Charlotte Louise, Valle, Juan W and Neoptolemos, John P
(2018) ACELARATE: A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with gemcitabine in patients with metastatic pancreatic carcinoma. .

Access the full-text of this item by clicking on the Open Access link.

Abstract

<jats:p> TPS537 </jats:p><jats:p> Background: Single agent gemcitabine still remains an appropriate choice for patients with metastatic pancreatic adenocarcinoma who are not suitable for combination therapy. Known resistance factors, such as low hENT1 and dCK, and CDA overexpression limit gemcitabine’s efficacy. NUC-1031 (Acelarin), is designed to overcome this resistance and deliver significantly higher intracellular levels of the active agent, dFdCTP, than gemcitabine. In Phase I studies Acelarin has shown activity in a range of metastatic cancers, including pancreatic, biliary and ovarian cancers. This Phase III study is designed to show superiority of Acelarin over gemcitabine in patients unsuitable for combination chemotherapy. Methods: To date, 85 patients have been randomised in this multicentre, Phase III study comparing Acelarin with gemcitabine first-line in patients with metastatic pancreatic adenocarcinoma. Patients must have a Performance Status of 0-2 and be unsuitable for combination chemotherapy. To detect a hazard ratio of 0.705 between the two arms, 270 events must be obtained from 328 patients, assuming a median survival of 6 months in the control arm. Currently, pts are being recruited at 27 centres. Patients receive either 825mg/m<jats:sup>2</jats:sup> Acelarin or 1000mg/m<jats:sup>2</jats:sup> gemcitabine on Day 1, 8 and 15 of a 28-day cycle until disease progression. The primary outcome measure is Overall Survival. Secondary outcome measures include Progression Free Survival, Response Rate, Disease Control Rate and Toxicity. Translational research will explore the use of biomarkers for predictive benefit of Acelarin over gemcitabine. Clinical trial information: ISRCTN16765355. </jats:p>

Item Type: Conference or Workshop Item (Unspecified)
Uncontrolled Keywords: Rare Diseases, Orphan Drug, Pancreatic Cancer, Clinical Trials and Supportive Activities, Clinical Research, Digestive Diseases, Cancer, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, 6 Evaluation of treatments and therapeutic interventions, Cancer
Depositing User: Symplectic Admin
Date Deposited: 27 Nov 2018 10:33
Last Modified: 16 Mar 2024 23:24
DOI: 10.1200/JCO.2018.36.4_suppl.TPS537
Open Access URL: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_...
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3028969